TABLE 5.

Multiple nonlinear regression analysis under Hill model (same data as those in Table 4)^a

PDP (unit)	PDP magnitude ± SE for each vancomycin product:				P value by CFA (IP vs GP)
	Lilly	Abbott	APP	Proclin
Emax (log10 CFU/g)	−5.65 ± 0.25 (<0.0001)	−5.65 ± 0.25 (<0.0001)	−5.65 ± 0.25 (<0.0001)	−5.65 ± 0.25 (<0.0001)	NA
ED50 (mg/kg/day)	62.7 ± 6.21b	1,877 ± 1,684d	270.7 ± 112.6c	129.5 ± 33.0c	<0.0001 (all)
N (Hill slope)	5.55 ± 2.67c	0.41 ± 0.14c	0.74 ± 0.25c	0.77 ± 0.16b	<0.0001 (all)
BD (mg/kg/day)	68.2 ± 1.26b	No bacteriostatic effect	No bacteriostatic effect	No bacteriostatic effect	NA
1LKD (mg/kg/day)	78.6 ± 1.57b	No bactericidal effect	No bactericidal effect	No bactericidal effect	NA

^aAbbreviations: GP, generic product; IP, innovator product; NA, nonapplicable.

^bP < 0.0001.

^cP between 0.0001 and 0.050.

^dP = 0.268.